Clinical evaluation of TrkB agonists will be required to determine the pharmacology of this pathway in man and the potential utility of TrkB agonist agents for body-weight regulatory disorders, such as obesity, anorexia or cachexia. Here, NTRK2 is linked to obesity due to melanocortin 4 receptor deficiency.